Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

800
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
800
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

477
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
477
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

756
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
756
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

300
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
300
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

319
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
319
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

604
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
604

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic cardiomyopathy unmasked by pregnancy: X-linked dystrophinopathy presenting as peripartum cardiomyopathy-a case report.

European heart journal. Case reports·2026
Same author

Comments and illustrations on the complementary use of contrast-enhanced (endoscopic) ultrasound in cardiac tumors.

Endoscopic ultrasound·2026
Same author

Deficiency of Inactive Rhomboid Protein 2 (iRhom2) Attenuates Macrophage Atherogenicity.

Biology·2026
Same author

On the crossroads of interdisciplinary medicine in amyloidosis - study protocol for a single-center interdisciplinary registry study.

PloS one·2026
Same author

Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study.

American heart journal plus : cardiology research and practice·2026
Same author

Screening for amyloidosis before aortic valve elective replacement: results from the SAVER study.

European journal of preventive cardiology·2026
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.9K

Levels of Circulating Intermediate Monocytes Decrease after Aortic Valve Replacement in Patients with Severe Aortic

Bernd Hewing1,2,3, Rena Ellerbroek1, Sebastian Chi-Diep Au1,3

  • 1Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.

Thrombosis and Haemostasis
|December 7, 2017
PubMed
Summary
This summary is machine-generated.

Aortic valve replacement, including surgical (SAVR) and transcatheter (TAVR) procedures, significantly reduces intermediate monocyte levels in patients with severe aortic stenosis (AS). This finding highlights the impact of valve function on immune cell distribution in this chronic inflammatory condition.

More Related Videos

Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

3.3K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.8K

Related Experiment Videos

Last Updated: Feb 17, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.9K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

3.3K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.8K

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Inflammation Research

Background:

  • Severe aortic stenosis (AS) is a chronic inflammatory condition.
  • Previous research links severe AS to elevated circulating intermediate monocyte levels.
  • Hemodynamics are known to influence monocyte subset distribution.

Purpose of the Study:

  • To investigate the effect of aortic valve replacement on circulating monocyte subset distribution in severe AS patients.
  • To compare changes in monocyte subsets following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).

Main Methods:

  • Flow cytometry was used to quantify classical, intermediate, and non-classical CD86-positive monocyte subsets.
  • Peripheral blood samples were analyzed from severe AS patients before and at 3- and 6-month follow-ups post-SAVR (n=25) or TAVR (n=44).
  • Absolute and relative levels of monocyte subsets were determined.

Main Results:

  • A significant decrease in absolute and relative levels of circulating intermediate monocytes was observed 6 months post-aortic valve replacement (p < 0.001).
  • The reduction in intermediate monocytes was evident between baseline and 6-month follow-up.
  • The decrease in intermediate monocytes occurred earlier after TAVR (between baseline and 3 months) compared to SAVR (between 3 and 6 months).

Conclusions:

  • Aortic valve replacement, via SAVR or TAVR, leads to a reduction in circulating intermediate monocyte levels in patients with severe AS.
  • These findings suggest that restoring normal hemodynamics through valve replacement impacts immune cell populations.
  • The timing of monocyte level normalization may differ between TAVR and SAVR procedures.